Show simple item record

dc.contributor.authorAltassan, Ruqaiah
dc.contributor.authorPeanne, Romain
dc.contributor.authorJaeken, Jaak
dc.contributor.authorBarone, Rita
dc.contributor.authorBidet, Muad
dc.contributor.authorBorgel, Delphine
dc.contributor.authorBrasil, Sandra
dc.contributor.authorCassiman, David
dc.contributor.authorCechova, Anna
dc.contributor.authorComan, David
dc.contributor.authorCorral, Javier
dc.contributor.authorCorreia, Joana
dc.contributor.authorde la Morena-Barrio, Maria Eugenia
dc.contributor.authorde Lonlay, Pascale
dc.contributor.authoret al.
dc.date.accessioned2019-10-04T04:00:06Z
dc.date.available2019-10-04T04:00:06Z
dc.date.issued2019
dc.identifier.issn0141-8955en_US
dc.identifier.doi10.1002/jimd.12024en_US
dc.identifier.urihttp://hdl.handle.net/10072/388080
dc.description.abstract© 2019 SSIEM Phosphomannomutase 2 (PMM2-CDG) is the most common congenital disorder of N-glycosylation and is caused by a deficient PMM2 activity. The clinical presentation and the onset of PMM2-CDG vary among affected individuals ranging from a severe antenatal presentation with multisystem involvement to mild adulthood presentation limited to minor neurological involvement. Management of affected patients requires a multidisciplinary approach. In this article, a systematic review of the literature on PMM2-CDG was conducted by a group of international experts in different aspects of CDG. Our managment guidelines were initiated based on the available evidence-based data and experts' opinions. This guideline mainly addresses the clinical evaluation of each system/organ involved in PMM2-CDG, and the recommended management approach. It is the first systematic review of current practices in PMM2-CDG and the first guidelines aiming at establishing a practical approach to the recognition, diagnosis and management of PMM2-CDG patients.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.publisherWileyen_US
dc.relation.ispartofpagefrom5en_US
dc.relation.ispartofpageto28en_US
dc.relation.ispartofissue1en_US
dc.relation.ispartofjournalJournal of Inherited Metabolic Diseaseen_US
dc.relation.ispartofvolume42en_US
dc.subject.fieldofresearchClinical Sciencesen_US
dc.subject.fieldofresearchcode1103en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsEndocrinology & Metabolismen_US
dc.subject.keywordsGenetics & Heredityen_US
dc.subject.keywordsMedicine, Research & Experimentalen_US
dc.titleInternational clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow upen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationAltassan, et al., International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up, Journal of Inherited Metabolic Disease, 2019, 42 (1), pp. 5-28en_US
dc.date.updated2019-10-04T03:54:24Z
gro.hasfulltextNo Full Text
gro.griffith.authorComan, Dave J.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record